Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib

In First-line Unresectable Hepatocellular CarcinomaTOKYO, May 25, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and...

More From BioPortfolio on "Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib"